Toggle Main Menu Toggle Search

Open Access padlockePrints

Human inherited complete STAT2 deficiency underlies inflammatory viral diseases

Lookup NU author(s): Dr Florian Gothe, Qian Zhang, Dr Christopher DuncanORCiD, Professor Sophie Hambleton

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Abstract

STAT2 is a transcription factor activated by type I and III interferons. We report 23 patients with loss of function variants causing autosomal recessive (AR), complete STAT2 deficiency. Both cells transfected with mutant STAT2 alleles and the patients' cells display impaired expression of interferon stimulated genes and impaired control of in-vitro viral infections. Clinical manifestations from early childhood onward include severe adverse reaction to live attenuated viral vaccines (LAV, 12/17 patients) and severe viral infections (10/23 patients), particularly critical influenza pneumonia (6 patients), critical COVID-19 pneumonia (1 patient), and herpes simplex encephalitis (1 patient). The patients display various types of hyperinflammation, often triggered by viral infection or after LAV administration, which probably attests to unresolved viral infection in the absence of STAT2-dependent type I and III IFN immunity (7 patients). Transcriptomic analysis reveals that circulating monocytes, neutrophils, and CD8 memory T cells contribute to this inflammation. Eight patients died (35%, 2 months-7 years): one of HSV-1 encephalitis, one of fulminant hepatitis, and six of heart failure during a febrile illness with no identified etiology. 15 patients remain alive (5-40 years). AR complete STAT2 deficiency underlies severe viral diseases, with half of the patients surviving into teenage years or adulthood.


Publication metadata

Author(s): Bucciol G, Moens L, Ogishi M, Rinchai D, Matuozzo D, Momenilandi M, Kerrouche N, Cale CM, Treffeisen ER, Al Salamah M, Al-Saud BK, Lachaux A, Duclaux-Loras R, Meignien M, Bousfiha A, Benhsaien I, Shcherbina A, Roppelt A, Gothe F, Houhou-Fidouh N, Hackett SJ, Bartnikas LM, Maciag MC, Alosaimi MF, Chou J, Mohammed RW, Freij BJ, Jouanguy E, Zhang SY, Boisson-Dupuis S, Beziat V, Zhang Q, Duncan CJ, Hambleton S, Casanova JL, Meyts I

Publication type: Article

Publication status: Published

Journal: Journal of Clinical Investigation

Year: 2023

Volume: 133

Issue: 12

Print publication date: 15/06/2023

Online publication date: 28/03/2023

Acceptance date: 24/03/2023

Date deposited: 28/06/2023

ISSN (print): 0021-9738

ISSN (electronic): 1558-8238

Publisher: American Society for Clinical Investigation

URL: https://doi.org/10.1172/JCI168321

DOI: 10.1172/JCI168321

PubMed id: 36976641


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
824110
ANR-10-IAHU-01
C16/18/007
ANR-10-LABX-62-IBEID
ANRS-COV05
EQU201903007798
European Union Horizon 2020
French National Research Agency
G0C8517N
G0E8420N
G0B5120N
MESRI-COVID-19
NIH
R01AI088364
R01AI163029
UL1TR001866
T32AI007512

Share